Disease relevance of DTPA-SMS

• We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia [1].
• Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide [2].
• In one patient with scintigraphic evidence of residual disease after two operations, radioguided surgery, using a hand-held gamma probe after iv administration of radiolabeled pentetreotide, was performed; this allowed detection and removal of residual multiple mediastinal lymph node metastases [3].
• Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-indium pentetreotide scan [4].
• Pentetreotide uptake was significantly greater in breast cancer patients compared to control patients [5].

High impact information on DTPA-SMS

• The SSTR2-infected cells bound 111In-pentetreotide sixfold more efficiently than control virus-infected cells and this binding was specifically blocked by nonradiolabeled pentetreotide [6].
• At the time of diagnosis, none of the patients had radiological evidence of the ectopic source of ACTH, whereas pentetreotide scintigraphy identified the lesion in two of four patients [3].
• The detection of radioiodine (I-131)-negative metastases of differentiated thyroid carcinoma (DTC) has been hitherto successfully tried by the well-known synthetic somatostatin analogue indium-111-labeled DTPA-octreotide (In-111 pentetreotide) [7].
• CONCLUSION: Pentetreotide scans may be regarded as a semiobjective tool in the evaluation of Graves' disease, both at initial stages as well as during treatment [8].
• Pentetreotide seems to have a high affinity for this MIBG-negative neuroblastoma cell line, which exhibited a clearly higher tumour uptake than the 2 other lines [9].

Chemical compound and disease context of DTPA-SMS

• CONCLUSION: Indium In-111 pentetreotide scintigraphy is a new innovative method for viewing neuroendocrine tumors [10].
• Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography [11].
• Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide [12].
• 111In-pentetreotide is unlikely to replace 123I-MIBG as a first-line routine diagnostic scintigraphic modality; compared to pentetreotide or MIBG, (V)DMSA seems to be highly sensitive only in medullary thyroid carcinomas [13].
• Diagnostic usefulness of radiolabeled pentetreotide scintigraphy and therapeutic efficiency of octreotide in a case of insulinoma [14].

Biological context of DTPA-SMS

• In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome [15].
• The clinical experience and the literature confirm that, among the wide variety of tracers and nuclear medicine modalities available today, metaiodobenzylguanidine (MIBG) and DTPA-D-Phe-octreotide (pentetreotide) are the radiopharmaceuticals of current clinical use [16].

Anatomical context of DTPA-SMS

• Thyroidal and orbital lymphocytic infiltration in Graves' disease, as well as identification of somatostatin receptors on lymphocytes, has provided a rationale for receptor imaging with the radiolabeled somatostatin analog pentetreotide [8].
• Indium In-111 pentetreotide scintigraphy: application to carotid body tumors [10].
• OBJECTIVE: To evaluate therapy with high doses of (111)Indium pentetreotide in a patient with bone metastases from a carcinoid of the pancreas [17].
• After surgery, pentetreotide scintigraphy showed pathologic uptake in the mediastinum not previously detected at surgery and only subsequently confirmed by radiologic studies [18].
• Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors [13].

Associations of DTPA-SMS with other chemical compounds

• After intravenous administration of a radiolabeled somatostatin analog (octreotide), an image of the thyroid gland is frequently observed; few data are available, however, on somatostatin receptors in epithelial thyroid cells assessed in vitro and on images of differentiated thyroid carcinoma (DTC) with pentetreotide scintigraphy [19].
• SRS was performed 1, 4 and 24 h after intravenous injection of 137-200 MBq of indium-111 pentetreotide [20].
• Since December 1993, in the 1st Nuclear Medicine Service of the University of Padua, eleven somatostatin-receptor scintigraphic studies with 111In-labelled pentetreotide have been performed [21].
• (123)I mIBG (meta-iodobenzylguanidine) and (111)In pentetreotide scintigraphy imaging modalities are useful in demonstrating neuroendocrine tumours [22].

Gene context of DTPA-SMS

• These results suggest that receptor-targeted radiotherapy with a 90Y-labelled octreotide analogue represents a new strategy for the treatment of SRIF-receptor-positive tumours that have been previously diagnosed with OctreoScan111 (pentetreotide) [23].
• Somatostatin receptor imaging was performed 4 h after the injection of 110 MBq of the somatostatin analogue indium-111 pentetreotide [24].
• The 111In-labeled SRIF analog SDZ 215-811 (OctreoScan 111) binds with a high affinity to somatostatin receptors and exhibits SRIF-like biological properties, as demonstrated by the inhibition of growth hormone release from pituitary cells [25].
• The incidental discovery of follicular thyroid cancer with in-111 pentetreotide scintigraphy in a patient with carcinoid tumor of the lung [26].
• Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide [27].

Analytical, diagnostic and therapeutic context of DTPA-SMS

• Finally, a chest computed tomography scan revealed the presence of a bronchial lesion in all patients, and pentetreotide scintigraphy identified four of six lesions [3].
• Indium-111 pentetreotide scintigraphy was performed in two patients for the localization of recurrent medullary thyroid carcinoma treated by surgery and external radiotherapy 1 and 10 years earlier [28].
• In 80 patients with TED, single-photon emission computed tomography (SPECT) images of the orbit were performed 4 and 24 hours after injection of Pentetreotide [29].
• Pentetreotide (a synthetic derivative of somatostatin) labelled with 111In has been used to localize tumours which possess surface or membrane receptors for somatostatin in vivo using a gamma camera (1) [30].
• 111Indium pentetreotide scanning is a safe, noninvasive method for early diagnosis of FP and is useful in detecting multicentric lesions [31].

References